[EN] COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE MODULATION DE L'ACTIVITÉ DE LA DÉSHYDROGÉNASE À CHAÎNE COURTE
申请人:UNIV CASE WESTERN RESERVE
公开号:WO2015065716A1
公开(公告)日:2015-05-07
Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.
[EN] INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS<br/>[FR] INHIBITEURS DE L'ACTIVITÉ DE LA DÉSHYDROGÉNASE À CHAÎNE COURTE POUR LE TRAITEMENT DE LA FIBROSE
申请人:UNIV CASE WESTERN RESERVE
公开号:WO2016144958A1
公开(公告)日:2016-09-15
A method of treating or preventing a fibrotic disease, disorder or condition includes administering to a subject in need of treatment a 15-PGDH inhibitor.
[EN] COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY<br/>[FR] COMPOSITIONS ET MÉTHODES POUR MODULER L'ACTIVITÉ 15-PGDH
申请人:UNIV CASE WESTERN RESERVE
公开号:WO2013158649A1
公开(公告)日:2013-10-24
Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors and 15-PGDH activators described herein.
COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY
申请人:Case Western Reserve University
公开号:US20150072998A1
公开(公告)日:2015-03-12
Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors and 15-PGDH activators described herein.
Compositions and methods of modulating 15-PGDH activity
申请人:CASE WESTERN RESERVE UNIVERSITY
公开号:US10301320B2
公开(公告)日:2019-05-28
Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors and 15-PGDH activators described herein.